RNA, U4 small nuclear 36, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-36P profile across patient tissues and cancer cell-line models. RNU4-36P expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RNU4-36P is differentially expressed in 7, with the highest sampling consensus in UCEC. Additionally, RNU4-36P RNA expression shows 9,709 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, UCEC, and THYM as cancer lineages where RNU4-36P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-36P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-36P survival associations across molecular data types. RNU4-36P RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-36P RNA expression–survival associations across cancer types. High RNU4-36P expression shows unfavorable associations in LIHC, PAAD, LGG, SKCM, KICH and SARC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RNU4-36P RNA expression.
This table summarizes RNU4-36P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-36P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-36P shows lower tumor expression in UCEC and STAD and higher tumor expression in LUAD, PRAD, LUSC and THCA. The UCEC box plot shows higher RNU4-36P RNA expression in normal versus tumor tissue (log2 FC = −0.955, t-test p = .002).
This table shows molecular features associated with RNU4-36P in patient tissues and cancer cell lines. In patient samples, RNU4-36P shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
